- Home
- CNMD vs SUPN Comparison
CNMD vs SUPN Comparison
Compare CNMD & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNMD
- SUPN
- Stock Information
- Founded
- CNMD 1970
- SUPN 2005
- Country
- CNMD United States
- SUPN United States
- Employees
- CNMD N/A
- SUPN N/A
- Industry
- CNMD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- SUPN Biotechnology: Pharmaceutical Preparations
- Sector
- CNMD Health Care
- SUPN Health Care
- Exchange
- CNMD Nasdaq
- SUPN Nasdaq
- Market Cap
- CNMD 1.7B
- SUPN 1.8B
- IPO Year
- CNMD 1987
- SUPN 2012
- Fundamental
- Price
- CNMD $56.94
- SUPN $32.25
- Analyst Decision
- CNMD Buy
- SUPN Hold
- Analyst Count
- CNMD 5
- SUPN 2
- Target Price
- CNMD $62.20
- SUPN $36.00
- AVG Volume (30 Days)
- CNMD 311.9K
- SUPN 459.3K
- Earning Date
- CNMD 07-30-2025
- SUPN 05-06-2025
- Dividend Yield
- CNMD 1.41%
- SUPN N/A
- EPS Growth
- CNMD 46.38
- SUPN N/A
- EPS
- CNMD 3.81
- SUPN 1.11
- Revenue
- CNMD $1,315,998,000.00
- SUPN $667,997,000.00
- Revenue This Year
- CNMD $6.27
- SUPN N/A
- Revenue Next Year
- CNMD $5.62
- SUPN $8.74
- P/E Ratio
- CNMD $14.93
- SUPN $29.13
- Revenue Growth
- CNMD 4.32
- SUPN 11.82
- 52 Week Low
- CNMD $46.00
- SUPN $25.53
- 52 Week High
- CNMD $78.58
- SUPN $40.28
- Technical
- Relative Strength Index (RSI)
- CNMD 50.54
- SUPN 46.77
- Support Level
- CNMD $54.77
- SUPN $31.32
- Resistance Level
- CNMD $58.27
- SUPN $32.85
- Average True Range (ATR)
- CNMD 1.63
- SUPN 0.77
- MACD
- CNMD -0.31
- SUPN -0.09
- Stochastic Oscillator
- CNMD 38.14
- SUPN 19.83
About CNMD CONMED Corporation
Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgeries. The firm currently reports through two reporting units, orthopedic surgery, and general surgery. From a geographic perspective, the firm is U.S.-centric, with maximum domestic sales accounting for revenue, EMEA accounting for second place, APAC at third, and the non-U.S. Americas region driving the remaining revenue.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.